Advances in human B19 erythrovirus biology.
Since its discovery, human parvovirus B19 (B19V), now termed erythrovirus, has been associated with many clinical situations (neurological and myocardium infections, persistent B19V DNAemia) in addition to the prototype clinical manifestations, i.e., erythema infectiosum and erythroblastopenia crisis. In 2002, the use of new molecular tools led to the characterization of three different genotypes of human B19 erythrovirus. Although the genomic organization is conserved, the geographic distribution of the different genotypes varies worldwide, and the nucleotidic divergences can impact the molecular diagnosis of B19 virus infection. The cell cycle of the virus remains partially unresolved; however, recent studies have shed light on the mechanism of cell entry and the interactions of B19V proteins with apoptosis pathways.
Servant-Delmas
Annabelle
A
Département des Agents Transmissibles par le Sang, Institut National de la Transfusion Sanguine, Paris, France.
Lefrère
Jean-Jacques
JJ
Morinet
Frédéric
F
Pillet
Sylvie
S
D017209:Apoptosis; D014644:Genetic Variation; D054884:Host-Pathogen Interactions; D006801:Humans; D017720:Molecular Epidemiology; D010322:Parvoviridae Infections / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology / Q000821:virology; D016732:Parvovirus B19, Human / Q000235:genetics* / Q000472:pathogenicity* / Q000502:physiology / Q000648:ultrastructure; D010802:Phylogeny; D053586:Virus Internalization; D014779:Virus Replication